Histogen Inc (HSTO)
0.3501
0.00 (0.00%)
USD |
OTCM |
Apr 25, 16:00
Histogen Cash from Financing (TTM): -0.017M for Sept. 30, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
September 30, 2023 | -0.017M |
June 30, 2023 | 4.405M |
March 31, 2023 | 3.798M |
December 31, 2022 | 3.323M |
September 30, 2022 | 6.064M |
June 30, 2022 | 1.649M |
Date | Value |
---|---|
March 31, 2022 | 8.016M |
December 31, 2021 | 27.08M |
September 30, 2021 | 28.29M |
June 30, 2021 | 29.63M |
March 31, 2021 | 24.38M |
December 31, 2020 | 5.783M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-0.017M
Minimum
Sep 2023
29.63M
Maximum
Jun 2021
11.87M
Average
5.924M
Median
Cash from Financing (TTM) Benchmarks
CEL-SCI Corp | 8.678M |
AIM ImmunoTech Inc | 0.485M |
IGC Pharma Inc | 2.856M |
NovaBay Pharmaceuticals Inc | 1.91M |
Protalix BioTherapeutics Inc | 24.67M |